Message from Serge Weinberg, Chairman of the Board of Directors

Dear shareholders
I would like to thank you for following the Sanofi General Meeting on May 10th. All the resolutions were adopted, in particular those continuing the progressive renewal of the Board of Directors. With the appointment of two new directors, the Board is largely independent (79%) and increasingly international and gender-balanced (43% women)...

Interview with Olivier Brandicourt, CEO

What are the highlights from the first quarter 2017 results?
I am very satisfied with the strong financial performance in the first quarter, which allows us to confirm our guidance for 2017...
What was the contribution of Emerging Markets?
Emerging Markets sales were up 8.5% in the first quarter. It is important to note that all our franchises are growing in these markets...

What can you tell us about the launches of Dupixent® and Kevzara® in the United States?
These launches lay the foundation for our new Immunology franchise and represent a major milestone for patients and healthcare professionals...

First Quarter 2017 Results

Results reflect the integration of Boehringer Ingelheim’s Consumer Healthcare business and Vaccines in Europe
First quarter 2017 results reflect the acquisition of the former Boehringer Ingelheim (BI) Consumer Healthcare business and the disposal of the Animal Health business (completed in almost all countries). They also reflect the consolidation of European operations related to Sanofi vaccine portfolio, following the termination of the Sanofi Pasteur MSD joint venture with Merck at the end of December 2016.


Dupixent® approved in the U.S.

For adults with moderate-to-severe atopic dermatitis (AD)
At the end of March 2017, Sanofi and Regeneron announced the approval in the U.S. of Dupixent® (dupilumab), the first and only biologic medicine approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable…

Kevzara® approved in the U.S.

In moderately to severely active rheumatoid arthritis

  • A new therapeutic option

  • A novel mechanism of action

  • The foundation of a new franchise

More news

  • Regulatory milestones in Europe for Kevzara® and Insulin lispro Sanofi®

  • Approval in Europe of Insulin lispro Sanofi®

  • Collaboration in the prevention of illnesses associated with respiratory syncytial virus

  • Executive Committee: Bill Sibold appointed Executive Vice President Sanofi Genzyme


Annual General Meeting 2017

Approval of a dividend of €2.96 per share
The Combined General Shareholders’ Meeting of Sanofi was held on May 10, 2017 in Paris. All resolutions submitted to the vote were adopted by its shareholders, among which the individual company and consolidated financial statements, the distribution of a cash dividend and the renewal of the Board of Directors.

Shareholder information

Shareholders Committee

The Individual Shareholders Committee was renewed at the beginning of the year following the call for applications launched in the Letter to Shareholders and on Sanofi’s website. It is now composed of twelve members, including ten shareholders selected according to their representativeness of Sanofi’s individual shareholders and for the first time, two students...

Shareholder handbook

The new edition of the Shareholder Handbook presents key figures for 2016 and the Group’s strategy. It provides information about Sanofi shares and how to manage them as well as practical information for shareholders. U.S. shareholders may also find details on the American Depositary Shares program. In addition, the handbook provides useful contact information and key shareholder events in 2017.

Share performance in Paris

On May 26, 2017, Sanofi had a market capitalization of more than €110bn.

Discover here the Sanofi
upcoming shareholder and
investor events


Contact the Individual Shareholder Relations team

54 rue La Boétie
75008 Paris FRANCE

France +33 800 075 876 •

United States +1 888 516 3002